Swedish Orphan Biovitrum AB (0MTD)

London
Currency in SEK
322.30
-8.80(-2.66%)
Closed
0MTD Scorecard
Full Analysis
Trading at a low P/E ratio relative to near-term earnings growth
Fair Value
Day's Range
319.60329.00
52 wk Range
243.20354.60
Key Statistics
Edit
Bid/Ask
315.60 / 329.00
Prev. Close
331.1
Open
328.4
Day's Range
319.6-329
52 wk Range
243.2-354.6
Volume
9.62K
Average Vol. (3m)
115.54K
1-Year Change
17.66%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
0MTD Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility
Show more

Swedish Orphan Biovitrum AB Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

Employees
1840

Compare 0MTD to Peers and Sector

Metrics to compare
0MTD
Peers
Sector
Relationship
P/E Ratio
29.2x−1.3x−0.6x
PEG Ratio
0.56−0.020.00
Price / Book
2.8x2.3x2.6x
Price / LTM Sales
4.4x6.0x3.1x
Upside (Analyst Target)
-150.0%48.8%
Fair Value Upside
Unlock29.1%7.5%Unlock

Earnings

Latest Release
Feb 05, 2025
EPS / Forecast
4.07 / 2.88
Revenue / Forecast
7.44B / 6.83B
EPS Revisions
Last 90 days

People Also Watch

51.900
G1AG
-0.76%
21.090
VOES
-1.26%
44.50
VOPA
-0.49%
303.6
INDT
-1.24%
503.00
SPL1
+0.72%

FAQ

What Is the Swedish Orphan Biovitrum (0MTD) Stock Price Today?

The Swedish Orphan Biovitrum stock price today is 322.30

What Stock Exchange Does Swedish Orphan Biovitrum Trade On?

Swedish Orphan Biovitrum is listed and trades on the London stock exchange.

What Is the Stock Symbol for Swedish Orphan Biovitrum?

The stock symbol for Swedish Orphan Biovitrum is "0MTD."

What Is the Swedish Orphan Biovitrum Market Cap?

As of today, Swedish Orphan Biovitrum market cap is 110.25B.

What is Swedish Orphan Biovitrum Earnings Per Share?

The Swedish Orphan Biovitrum EPS is 11.37.

What Is the Next Swedish Orphan Biovitrum Earnings Date?

Swedish Orphan Biovitrum will release its next earnings report on Apr 29, 2025.

From a Technical Analysis Perspective, Is 0MTD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.